Charles Schwab Investment Management Inc Krystal Biotech, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 220,439 shares of KRYS stock, worth $40.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
220,439
Previous 188,903
16.69%
Holding current value
$40.3 Million
Previous $33.6 Million
20.44%
% of portfolio
0.01%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding KRYS
# of Institutions
266Shares Held
25MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$721 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$524 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$445 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$244 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$187 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.69B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...